NEW YORK (GenomeWeb) – For patients who have ALK-positive, advanced non-small cell lung cancer tumors and have stopped responding to Pfizer’s Xalkori (crizotinib), the US Food and Drug Administration this week approved a new option from Novartis called Zykadia (ceritinib).
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.